08:17 AM EDT, 03/31/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that the Australian Therapeutic Goods Administration approved mRESVIA, an mRNA vaccine designed to prevent lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 and older.

The company said the approval of mRESVIA, the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19, is based on results from a phase 3 trial.